Clinical mitochondrial dysfunction in uninfected children born to HIV-infected mothers following perinatal exposure to nucleoside analogues

Environmental and Molecular Mutagenesis

Volumn 48, Issue 3-4, 2007, Pages 173-178

  Benhammou, Valérie ^a   Tardieu, Marc ^a   Warszawski, Josiane ^a   Rustin, Pierre ^b   Blanche, Stéphane ^c,d  

^a BICÊTRE HOSPITAL   (France)

^b HÔPITAL ROBERT DEBRÉ   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Children; Mitochondria; Pregnancy; Zidovudine

Indexed keywords

LAMIVUDINE; NUCLEOSIDE ANALOG; ZIDOVUDINE;

ACIDOSIS; CLINICAL FEATURE; COHORT ANALYSIS; DISEASE ASSOCIATION; DISEASE COURSE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG MEGADOSE; FRANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLACTATEMIA; MITOCHONDRIAL TOXICITY; NEUROTOXICITY; NONHUMAN; PERINATAL DRUG EXPOSURE; PERINATAL PERIOD; PREGNANT WOMAN; REVIEW; VIRUS TRANSMISSION;

ANTI-HIV AGENTS; CHILD; FEMALE; HIV INFECTIONS; HUMANS; MITOCHONDRIAL DISEASES; MOTHERS; NUCLEOSIDES; PREGNANCY; REVERSE TRANSCRIPTASE INHIBITORS;

ANIMALIA;

EID: 34047242828     PISSN: 08936692     EISSN: 10982280     Source Type: Journal    
DOI: 10.1002/em.20279     Document Type: Review

References (42)

1. Abrams EJ. 2004. Prevention of mother-to-child transmission of HIV-successes, controversies and critical questions. AIDS Rev 6:131-143.
2. Alimenti A, Burdge DR, Ogilvie GS, Money DM, Forbes JC. 2003. Lactic acidemia in human immunodeficiency virus-uninfected infants exposed to perinatal antiretroviral therapy. Pediatr Infect Dis J 22:782-789.
3. Barret B, Tardieu M, Rustin P, Lacroix C, Chabrol B, Desguerre I, Dollfus C, Mayaux MJ, Blanche S; For the French Perinatal Cohort Study Group. 2003. Persistent mitochondrial dysfunction in HIV-1-exposed but uninfected infants: Clinical screening in a large prospective cohort. AIDS 17:1769-1785.
4. Blanche S, Tardieu M, Rustin P, Slama A, Barret B, Firtion G, Ciraru-Vigneron N, Lacroix C, Rouzioux C, Mandelbrot L, Desguerre I, Rotig A, Mayaux MJ, Delfraissy JF. 1999. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet 354:1084-1089.
5. Brinkman K. 2001. Evidence for mitochondrial toxicity: Lactic acidosis as proof of concept. J HIV Ther 6:13-16.
6. Brinkman K, ter Hofstede HJ, Burger DM, Smeitink JA, Koopmans PP. 1998. Adverse effects of reverse transcriptase inhibitors: Mitochondrial toxicity as common pathway. AIDS 12:1735-1744.
7. Bulterys M, Nesheim S, Abrams EJ, Palumbo P, Parley J, Lampe M, Fowler MG; Perinatal Safety Review Working Group. 2000. Lack of evidence of mitochondrial dysfunction in the offspring of HIV-infected women. Retrospective review of perinatal exposure to antiretroviral drugs in the Perinatal AIDS Collaborative Transmission Study. Ann N Y Acad Sci 918:212-221.
8. Chretien D, Rustin P. 2003. Mitochondrial oxidative phosphorylation: Pitfalls and tips in measuring and interpreting enzyme activities. J Inherit Metab Dis 26:189-198.
9. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan MJ, VanDyke R, Bey M, Shearer W, Jacobson RL, Jimenez E, O'Neill E, Bazin B, Delfraissy J-F, Culnane M, Coombs R, Elkins M, Moye J, Stratton P, Balsley J; for The Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. 1994. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 331:1173-1180.
10. Cooper ER, DiMauro S, Sullivan M, Jones-Eaves E, Kay L, Moloney C, Regan AM. 2004. Biopsy-confirmed mitochondrial dysfunction in an HIV-exposed infant whose mother received combination antiretrovirals during the last 6 weeks of pregnancy. XV. International AIDS conference Bangkok 11-16 July 2004, Abstract number: TuPeB4394.
11. Culnane M, Fowler M, Lee SS, McSherry G, Brady M, O'Donnell K, Mofenson L, Gortmaker SL, Shapiro DE, Scott G, Jimenez E, Moore EC, Diaz C, Flynn PM, Cunningham B, Oleske J. 1999. Lack of long-term effects of in utero exposure to zidovudine among uninfected children born to HIV-infected women. Pediatric AIDS Clinical Trials Group Protocol 219/076 Teams. JAMA 281:151-157.
12. Darin N, Oldfors A, Moslemi AR, Holme E, Tulinius M. 2001. The incidence of mitochondrial encephalomyopathies in childhood: clini-cal features and morphological, biochemical, and DNA anbormalities. Ann Neurol 49:377-383.
13. Divi RL, Walker VE, Wade NA, Nagashima K, Seilkop SK, Adams ME, Nesel CJ, O'Neill JP, Abrams EJ, Poirier MC. 2004. Mitochondrial damage and DNA depletion in cord blood and umbilical cord from infants exposed in utero to Combivir. AIDS 18:1013-1021.
14. European Collaborative Study. 2003. Exposure to antiretroviral therapy in utero or early life: The health of uninfected children born to HIV-infected women. J Acquir Immune Defic Syndr 32:380-387.
15. Ewings EL, Gerschenson M, St. Claire MC, Nagashima K, Skopets B, Harbaugh SW, Harbaugh JW, Poirier MC. 2000. Genotoxic and functional consequences of transplacental zidovudine exposure in fetal monkey brain mitochondria. J Acquir Immune Defic Syndr 24:100-105.
16. Fleming TR. 2000. Evaluating the safety of interventions for prevention of perinatal transmission of HIV. Ann N Y Acad Sci 918:201-211.
17. Gerschenson M, Erhart SW, Paik CY, St. Claire MC, Nagashima K, Skopets B, Harbaugh SW, Harbaugh JW, Quan W, Poirier MC. 2000a. Fetal mitochondrial heart and skeletal muscle damage in Erythrocebus patas monkeys exposed in utero to 3′-azido-3′-deoxythymidine. AIDS Res Hum Retroviruses 16:635-644.
18. Gerschenson M, Poirier MC. 2000b. Fetal patas monkeys sustain mitochondrial toxicity as a result of in utero zidovudine exposure. Ann N Y Acad Sci 918:269-281.
19. Gerschenson M, Nguyen V, Ewings EL, Ceresa A, Shaw JA, St. Claire MC, Nagashima K, Harbaugh SW, Harbaugh JW, Olivero OA, Divi RL, Albert PS, Poirier MC. 2004. Mitochondrial toxicity in fetal Erythrocebus patas monkeys exposed transplacentally to zidovudine plus lamivudine. AIDS Res Hum Retroviruses 20:91-100.
20. Giaquinto C, De Romeo A, Giacomet V, Rampon O, Ruga E, Burlina A, De Rossi A, Sturkenboom M, D'Elia R. 2001. Lactic acid levels in children perinatally treated with antiretroviral agents to prevent HIV transmission. AIDS 15:1074-1075.
21. Koren G, Pastuszak A, Ito S. 1998. Drugs in pregnancy. N Engl J Med 338:1128-1137.
22. Lewis W, Dalakas MC. 1995. Mitochondrial toxicity of antiviral drugs. Nat Med 1:417-421.
23. Lindegren ML, Rhodes P, Gordon L, Fleming P;Perinatal Safety Review Working Group; State and Local Health Department HIV/AIDS Surveillance Programs. 2000. Drug safety during pregnancy and in infants. Lack of mortality related to mitochondrial dysfunction among perinatally HIV-exposed children in pediatric HIV surveillance. Ann N Y Acad Sci 918:222-235.
24. Lipshultz SE, Easley KA, Orav EJ, Kaplan S, Stare TJ, Bricker JT, Lai WW, Moodie DS, Sopko G, McIntosh K, Colan SD. 2000. Absence of cardiac toxicity of zidovudine in infants. Pediatric Pulmonary and Cardiac Complications of Vertically Transmitted HIV Infection Study Group. N Engl J Med 343:759-766.
25. Mandelbrot L, Landreau-Mascaro A, Rekacewicz C, Berrebi A, Benifla JL, Burgard M, Lachassine E, Barret B, Chaix ML, Bongain A, Ciraru-Vigneron N, Crenn-Hebert C, Delfraissy JF, Rouzioux C, Mayaux MJ, Blanche S; Agence Nationale de Recherches sur le SIDA (ANRS) 075 Study Group. 2001. Lamivudine-zidovudine combination for prevention of maternal-infant transmission of HIV-1. JAMA 285:2083-2093.
26. Moyle G. 2000. Toxicity of antiretroviral nucleoside and nucleotide analogues: Is mitochondrial toxicity the only mechanism? Drug Saf 23:467-481.
27. Munnich A, Rustin P. 2001. Clinical spectrum and diagnosis of mitochondrial disorders. Am J Med Genet 106:4-17.
28. Nolan D, Mallal S. 2004. Complications associated with NRTI therapy: Update on clinical features and possible pathogenic mechanisms. Antivir Ther 9:849-863.
29. Noguera A, Fortuny C, Munoz-Almagro C, Sanchez E, Vilaseca MA, Artuch R, Pou J, Jimenez R. 2004. Hyperlactatemia in human immunodeficiency virus-uninfected infants who are exposed to antiretrovirals. Pediatrics 114:e598-e603.
30. Paul ME, Chantry CJ, Read JS, Frederick MM, Lu M, Pitt J, Turpin DB, Cooper ER, Handelsman EL. 2001. Morbidity and mortality during the first two years of life among uninfected children born to human immunodeficiency virus type 1-infected women: The women and infants transmission study. Pediatr Infect Dis J 24:46-56.
31. Perinatal Safety Review Working Group. 2000. Nucleoside exposure in the children of HIV-infected women receiving antiretroviral drugs: Absence of clear evidence for mitochondrial disease in children who died before 5 years of age in five United States cohorts. JAIDS 25:261-268.
32. Poirier MC, Patterson TA, Slikker W Jr, Olivero OA. 1999. Incorporation of 3′-azido-3′-deoxythymidine (AZT) into fetal DNA, fetal tissue distribution of drug after infusion of pregnant late-term rhesus macaques with a human-equivalent AZT dose. J Acquir Immune Defic Syndr 22:477-483.
33. Poirier MC, Divi RL, Al-Harthi L, Olivero OA, Nguyen V, Walker B, Landay AL, Walker VE, Charurat M, Blattner WA;Women and Infants Transmission Study (WITS) Group. 2003. Long-term mitochondrial toxicity in HIV-uninfected infants born to HIV-infected mothers. J Acquir Immune Defic Syndr 33:175-183.
34. Rubin DB. 1997. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 127:757-763.
35. Scalfaro P, Chesaux JJ, Buchwalder PA, Biollaz J, Micheli JL. 1998. Severe transient neonatal lactic acidosis during prophylactic zidovudine treatment. Intensive Care Med 24:247-250.
36. Schmiedel J, Jackson S, Schafer J, Reichmann H. 2003. Mitochondrial cytopathies. J Neurol 250:267-277.
37. Shiramizu B, Shikuma KM, Kamemoto L, Gerschenson M, Erdem G, Pinti M, Cossarizza A, Shikuma C. 2003. Placenta and cord blood mitochondrial DNA toxicity in HIV-patient women receiving nucleoside reverse transcriptase inhibitors during pregnancy. JAIDS 32:370-374.
38. Sperling RS, Shapiro DE, McSherry GD, Britto P, Cunningham BE, Culnane M, Coombs RW, Scott G, Van Dyke RB, Shearer WT, Jimenez E, Diaz C, Harrison DD. Delfraissy JF. 1998. Safety of the maternal-infant zidovudine regimen utilized in the Pediatric AIDS Clinical Trial Group 076 Study. AIDS 12:1805-1813.
39. Tardieu M, Brunelle F, Raybaud C, Ball W, Barret B, Pautard B, Lachassine E, Mayaux MJ, Blanche S. 2005. Cerebral MR Imaging in uninfected children born to HIV-seropositive mothers and perinatally exposed to Zidovudine. Am J Neuroradiol 26:695-701.
40. Uusimaa J, Remes AM, Rantala H, Vainionpaa L, Herva R, Vuopala K, Nuutinen M, Majamaa K, Hassinen IE. 2000. Childhood encephalopathies and myopathies: A prospective study in a defined population to assess the frequency of mitochondrial disorders. Pediatrics 105:598-603.
41. Vermund SH. 2004. Prevention of mother-to-child transmission of HIV in Africa. Top HIV Med 12:130-134.
42. Walker DM, Poirier MC, Campen MJ, Cook DL Jr. Divi RL, Nagashima K, Lund AK, Cossey PY, Hahn FF, Walker VE. 2004. Persistence of mitochondrial toxicity in hearts of female B6C3F1 mice exposed in utero to 3′-azido-3′- deoxythymidine. Cardiovasc Toxicol 4:133-153.